文献速递血栓与止血淋巴瘤

特发性多中心型Castleman病中观察到的免疫介导性血小板减少和IL-6介导的血小板增多

Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease.
PubMed 文献 · Br J Haematol · 2024-01-02

该研究分析了63例特发性多中心型Castleman病(iMCD)患者的血常规、临床实验室指标和血涂片形态,按临床亚型分组。结果显示iMCD-TAFRO患者血小板体积大,临床严重程度与血小板计数降低及输血难治性血小板减少相关;iMCD-IPL患者血小板计数升高与IL-6升高相关,抗IL-6治疗后下降。数据提示自身免疫机制参与部分iMCD-TAFRO患者的血小板减少,而IL-6驱动iMCD-IPL的血小板增多。

要点

  • iMCD-TAFRO患者表现为大血小板,临床严重程度与较低血小板计数及输血难治性血小板减少相关。
  • iMCD-IPL患者血小板计数升高与IL-6升高相关,抗IL-6治疗后血小板计数下降。
  • 数据提示自身免疫机制参与至少部分iMCD-TAFRO患者的血小板减少,IL-6驱动iMCD-IPL的血小板增多。

核心结论

  • 数据提示自身免疫机制参与至少部分iMCD-TAFRO患者的血小板减少,而IL-6驱动iMCD-IPL的血小板增多,这些机制可能参与疾病发病。

研究设计与样本

  • 分析63例iMCD患者的完整血细胞计数、其他临床实验室值和血涂片形态,按临床亚型分组。

主要发现

  • iMCD-TAFRO患者有大血小板,临床严重程度与较低血小板计数和输血难治性血小板减少相关,类似于免疫性血小板减少性紫癜中观察到的免疫介导性血小板破坏。
  • iMCD-IPL患者血小板计数升高与IL-6升高相关,抗IL-6治疗后血小板计数下降。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Idiopathic multicentric Castleman disease (iMCD) is a rare haematological disorder characterized by generalized lymphadenopathy with atypical histopathological features and systemic inflammation caused by a cytokine storm involving interleukin-6 (IL-6). Three clinical subtypes are recognized: thrombocytopenia, anasarca, fever, renal dysfunction, organomegaly (iMCD-TAFRO); idiopathic plasmacytic lymphadenopathy (iMCD-IPL), involving thrombocytosis and hypergammaglobulinaemia; and iMCD-not otherwise specified (iMCD-NOS), which includes patients who do not meet criteria for the other subtypes. Disease pathogenesis is poorly understood, with potential involvement of infectious, clonal and/or autoimmune mechanisms. To better characterize iMCD clinicopathology and gain mechanistic insights into iMCD, we analysed complete blood counts, other clinical laboratory values and blood smear morphology among 63 iMCD patients grouped by clinical subtype. Patients with iMCD-TAFRO had large platelets, clinical severity associated with lower platelet counts and transfusion-resistant thrombocytopenia, similar to what is observed with immune-mediated destruction of platelets in immune thrombocytopenic purpura. Conversely, elevated platelet counts in iMCD-IPL were associated with elevated IL-6 and declined following anti-IL-6 therapy. Our data suggest that autoimmune mechanisms contribute to the thrombocytopenia in at least a portion of iMCD-TAFRO patients whereas IL-6 drives thrombocytosis in iMCD-IPL, and these mechanisms likely contribute to disease pathogenesis.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Rubenstein AI, Pierson SK, Shyamsundar S, et al. Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease. Br J Haematol. 2024. PMID: 38168727. doi:10.1111/bjh.19279

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。